1 / 4

PMX 2058 Efficacy: Panc-1 Xenografts (2)

PMX 2058 Efficacy: Panc-1 Xenografts (2). Insert available PK data – awaited Insert available PD data (HIF-1 , VEGF, GLUT-1 and CD31) - awaited. Strictly confidential. PMX 2058 Efficacy: BxPC3 Xenografts (1). Efficacy data supported by PK and PD data – data to be generated.

ranit
Télécharger la présentation

PMX 2058 Efficacy: Panc-1 Xenografts (2)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. PMX 2058 Efficacy: Panc-1 Xenografts (2) Insert available PK data – awaited Insert available PD data (HIF-1, VEGF, GLUT-1 and CD31) - awaited. Strictly confidential

  2. PMX 2058 Efficacy: BxPC3 Xenografts (1) Efficacy data supported by PK and PD data – data to be generated. Strictly confidential

  3. PMX 2058 Efficacy: BxPC3 Xenografts (2) BWL – Body weight loss Interim data - No statistical analysis currently available. Strictly confidential

  4. PMX 2058: Comparison of Panc-1 and BxPC3 Xenograft Models Other differences in model to consider? Strictly confidential

More Related